What are the best treatments for Neurofibromatosis?

Treatment for Neurofibromatosis is highly personalized and focuses on managing specific complications, as there is currently no single cure for the underlying genetic condition. Management typically involves a multidisciplinary team to monitor for tumor growth, address dermatological concerns, and provide supportive care for associated neurological or orthopedic issues.

What are the current first-line treatments for Neurofibromatosis?

Because Neurofibromatosis (both NF1 and NF2) presents differently in every patient, there is no "one-size-fits-all" treatment. The primary clinical approach is proactive surveillance. Physicians monitor for the development of plexiform neurofibromas, optic pathway gliomas, or skeletal abnormalities. When tumors become symptomatic or pose a health risk, intervention becomes necessary. For many, the goal is to manage symptoms, preserve function, and improve quality of life through regular clinical assessments, including annual physical exams, ophthalmological evaluations, and imaging studies when indicated.

What medications are used to treat Neurofibromatosis?

Pharmacological options have evolved significantly in recent years. For patients with inoperable, symptomatic plexiform neurofibromas associated with Neurofibromatosis type 1, the MEK inhibitor selumetinib (Koselugo) has been approved by the FDA. This medication works by inhibiting specific proteins that contribute to tumor growth. Other medications are often prescribed to manage the comorbidities of Neurofibromatosis, such as antihypertensives for renal artery stenosis, or anticonvulsants for patients who experience seizures.

What are the non-pharmacological and surgical treatment options?

Surgery remains a cornerstone for treating Neurofibromatosis when tumors cause pain, disfigurement, or compress vital structures. However, surgical removal is not always possible due to the tumor's location or involvement with nerves. Other non-pharmacological interventions include:

• Physical and Occupational Therapy: Essential for patients experiencing muscle weakness, balance issues, or skeletal complications like scoliosis.


• Radiation Therapy: Generally used with extreme caution, as individuals with Neurofibromatosis have a higher risk of developing secondary malignancies following radiation.


• Pain Management: Specialized clinics focusing on chronic pain can assist with neuropathic pain management through nerve blocks or specialized therapeutic regimens.

Which specialists should be on a Neurofibromatosis care team?

Effective management of Neurofibromatosis requires a coordinated, multidisciplinary approach. Patients often benefit from a "medical home" model involving several key specialists:

1. Geneticist/Genetic Counselor: To confirm the diagnosis and discuss inheritance patterns.


2. Neurologist/Neuro-oncologist: To monitor tumor growth and neurological function.


3. Dermatologist: To monitor café-au-lait spots and cutaneous neurofibromas.


4. Orthopedist: To address bone dysplasia and scoliosis.


5. Ophthalmologist: To check for Lisch nodules and optic gliomas.


6. Psychologist: To support the emotional and social impacts of living with a visible, chronic condition.

Next steps

• Consult with a dedicated Neurofibromatosis specialist at an academic medical center or a specialized NF clinic.


• Join the DiseaseMaps.org community of 725+ members to share experiences and find local support.


• Explore ongoing clinical trials through the NIH or NF-specific foundations to see if emerging therapies may be appropriate for your specific clinical profile.


• Maintain a comprehensive "health passport" that tracks your tumor monitoring history, imaging results, and specialist consultations.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult your personal healthcare team to develop a treatment plan tailored to your specific clinical needs.

References

• NIH Genetic and Rare Diseases (GARD) Information Center: Neurofibromatosis Type 1 and Type 2.


• Children's Tumor Foundation: Clinical Care Guidelines for Neurofibromatosis.


• Orphanet: Rare Disease Database (ORPHA:636).


• OMIM (Online Mendelian Inheritance in Man): Neurofibromatosis, Type 1 (#162200).